SAILIFE · NSE
Sai Life Sciences Limited
₹1,800.7
+0.69% (+₹12.3)
Prev. close
₹1,788.4
Volume
6,17,754
Delivery %
35.2%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Sai Life Sciences, recommending a buy at ₹1440 with a target of ₹1480 and a stop loss at ₹1420 for today's tr…” | Vaishali ParekhPrabhudas Lilladher | Sai Life Sciences | HIT | |
| “SAILIFE has given a previous swing high breakout, increasing positive sentiment, and is sustaining above its 21 EMA and …” | Rupak DeLKP Securities | Sai Life Sciences | HIT | |
| “Bullish on Sai Life Sciences Limited, recommending a buy at ₹890–910 with a target price of ₹1050 in two to three months…” | Marketsmith India AnalysisMarketsmith India | Sai Life Sciences | MISS | |
| “Recommends buying Sai Life Sciences at ₹883, targeting ₹950, with a stop loss at ₹850, based on a breakout strategy.” | Sumeet BagadiaChoice Equity Broking | Sai Life Sciences | HIT | |
| “Recommends buying Sai Life Sciences at ₹898, targeting ₹965, with a stop loss at ₹865, based on a breakout strategy.” | Sumeet BagadiaChoice Equity Broking | Sai Life Sciences | MISS | |
| “Bullish on Sai Life Sciences, recommending a buy with a price target of ₹1,100, implying a 26% upside. Improved project …” | Jefferies AnalysisJefferies | Sai Life Sciences | HIT | |
| “Initiated with a 'Buy' rating on SAI Life Sciences, setting a target price of Rs 1,100, implying a 19% upside from its l…” | Jefferies AnalysisJefferies | Sai Life Sciences | HIT | |
| “Short-term traders should consider buying Sai Life Sciences, targeting Rs 890 within the next 1-2 months. The stock has …” | ETMarkets AnalysisETMarkets.com | Sai Life Sciences | HIT | |
| “Bullish on Sai Life Sciences Ltd, recommending a buy at ₹789 with a target price of ₹920 in two to three months and a st…” | Marketsmith India AnalysisMarketsmith India | Sai Life Sciences | HIT | |
| “Bullish on Sai Life Sciences with a buy range of ₹720–745, targeting ₹865, and a stop loss at ₹678. The timeframe for th…” | Marketsmith India AnalysisMarketsmith India | Sai Life Sciences | MISS |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends buying Sai Life Sciences within the ₹720–745 range, targeting a profit goal of ₹865 with a stop loss at ₹678,…” | Marketsmith India AnalysisMarketsmith India | Sai Life Sciences | — |
Fundamentals
About Sai Life Sciences Limited
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It offers medicinal chemistry, pharmacokinetics, clinical and commercial manufacturing, and process development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Krishnam Raju Kanumuri
Headquarters
Hyderabad
Employees
5,224
Website
sailife.comExchange
View on NSE ↗Key stats
Market cap
₹32,850.41 Cr
P/E ratio (TTM)
91.3
Dividend yield
0.00%
EPS (TTM)
₹16.93
Beta (1Y · daily vs NIFTY 50)
0.72
Shares float
13.33 Cr
EPS · quarter ended Jun 2026
₹3.42
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,196.95 Cr | ₹1,456.47 Cr | ₹1,660.39 Cr | ₹2,153.23 Cr | |
EBITDA | ₹192.90 Cr | ₹314.58 Cr | ₹442.44 Cr | ₹672.29 Cr |
| ₹9.99 Cr | ₹82.81 Cr | ₹170.13 Cr | ₹348.91 Cr | |
Diluted EPS | ₹0.48 | ₹3.98 | ₹8.61 | ₹16.08 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2026 could not be checked against the company's own annual report: this page shows ₹348.91 Cr while the annual report gives ₹341.48 Cr (2.1% apart).
EBITDA for Mar 2026 could not be checked against the company's own annual report: this page shows ₹672.29 Cr while the annual report gives ₹641.09 Cr (4.6% apart).
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹2,186.65 Cr | ₹2,275.14 Cr | ₹3,159.98 Cr | ₹3,626.14 Cr | |
| ₹932.38 Cr | ₹927.66 Cr | ₹352.38 Cr | ₹288.45 Cr | |
Stockholders' equity | ₹888.09 Cr | ₹975.14 Cr | ₹2,128.36 Cr | ₹2,483.69 Cr |
CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹219.40 Cr | ₹263.09 Cr | ₹314.05 Cr | ₹509.13 Cr | |
Investing cash flow | ₹-101.78 Cr | ₹-192.38 Cr | ₹-536.67 Cr | ₹-395.41 Cr |
| ₹-200.65 Cr | ₹-95.30 Cr | ₹301.43 Cr | ₹-123.68 Cr | |
Capital expenditure | ₹-113.08 Cr | ₹-181.69 Cr | ₹-369.28 Cr | ₹-592.96 Cr |
End cash position | ₹35.53 Cr | ₹11.97 Cr | ₹91.05 Cr | ₹81.91 Cr |
Dividends paid has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|
| Promoter | 35.24% | 35.17% | 35.15% | 34.94% | 34.70% | 34.61% | 34.53% |
| Public | 64.76% | 64.83% | 64.85% | 65.06% | 65.30% | 65.39% | 65.47% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Sai Life Sciences Limited | ₹32,875.91 Cr | ₹1,558.2 | 91.4 | 13.24 | 14.0% | 0.12 | +28.7% | +68.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.